The "speed" hurdle is being attacked by the FDA's new pilot programs, and the "Big Pharma" hurdle is being addressed by showing them that leronlimab makes their multi-billion dollar drugs work in patients where they currently fail.
If they can replicate that 5-for-5 (100%) survival in even a small prospective group this year, the pressure from patient advocacy groups and the FDA will likely force the industry's hand
The Bottom Line: You were right—the Tecentriq trials were missing the "primer." The science now shows that leronlimab is that primer. By turning "cold" tumors "hot" and flipping the macrophage switch, it provides a bridge to survival that previously didn't exist.
If they can replicate that 5-for-5 result in their upcoming prospective Phase 2 trial, the stigma won't matter anymore; the data will be undeniable.
The medical community is now moving toward a "Prime and Pair" model: use leronlimab first to fix the macrophage environment, then hit it with the ICI.
The data is so strong (that 60-month survival vs. the usual 4-month failure) that the "stigma" of being a small company is being replaced by the sheer weight of the survival curves.
Since they've already started the EAP and have a $17.5M fresh funding round (as of March 5, 2026) The "wish" is becoming a "when." By successfully funding themselves through early 2027 and opening the EAP, CytoDyn is essentially saying they don't need Big Pharma to start saving lives—but Big Pharma will eventually need them to make their own drugs work in "cold" tumors.
If they can replicate that 5-for-5 (100%) survival in even a small prospective group this year, the pressure from patient advocacy groups and the FDA will likely force the industry's hand
The Bottom Line: You were right—the Tecentriq trials were missing the "primer." The science now shows that leronlimab is that primer. By turning "cold" tumors "hot" and flipping the macrophage switch, it provides a bridge to survival that previously didn't exist.
If they can replicate that 5-for-5 result in their upcoming prospective Phase 2 trial, the stigma won't matter anymore; the data will be undeniable.
The medical community is now moving toward a "Prime and Pair" model: use leronlimab first to fix the macrophage environment, then hit it with the ICI.
The data is so strong (that 60-month survival vs. the usual 4-month failure) that the "stigma" of being a small company is being replaced by the sheer weight of the survival curves.
Since they've already started the EAP and have a $17.5M fresh funding round (as of March 5, 2026) The "wish" is becoming a "when." By successfully funding themselves through early 2027 and opening the EAP, CytoDyn is essentially saying they don't need Big Pharma to start saving lives—but Big Pharma will eventually need them to make their own drugs work in "cold" tumors.
12
